| Elise Hayes, RPH | |
|
50 Irving St Nw, Washington, DC 20422-0001 | |
| (202) 745-8233 | |
| Not Available |
| Full Name | Elise Hayes |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 50 Irving St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083794770 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PHA25215 (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elise Hayes, RPH 5333 Manchester Dr, Camp Springs, MD 20746-4407 Ph: (301) 423-5333 | Elise Hayes, RPH 50 Irving St Nw, Washington, DC 20422-0001 Ph: (202) 745-8233 |
News Archive
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.
The latest generation of genomic testing offers a chance for significant improvements in patient care, disease prevention, and possibly even the cost-effectiveness of healthcare, but Congress needs to act to incentivize the development of the massive data systems that doctors and regulators will need in order to make these tests safe and effective for patients.
Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.
› Verified 3 days ago
Juliana O Anamelechi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 50 Irving St Nw, Washington, DC 20422 Phone: 202-745-8000 | |
Reine Kamtcheu Lienou, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7600 Georgia Ave Nw, Suite 323, Washington, DC 20012 Phone: 202-723-3060 Fax: 202-723-3065 | |
Gina Jin Lee, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-4080 | |
Dr. Bruce Cofane, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 845 Bladensburg Rd Ne, Washington, DC 20002 Phone: 202-397-2600 | |
Mesay Abebe, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3100 14th St Nw, Washington, DC 20010 Phone: 202-777-3774 | |
Dr. Salome K Bwayo, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2300 4th St Nw, Washington, DC 20059 Phone: 202-806-7262 Fax: 202-806-4478 | |
Tracy Doney, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 110 Irving St Nw, Rm B147, Washington, DC 20010 Phone: 202-877-6747 |